Cargando…
A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers
Clinically, different approaches are adopted worldwide for the treatment of cancer, which still ranks second among all causes of death. Immunotherapy for cancer treatment has been the focus of attention in recent years, aiming for an eventual antitumoral effect through the immune system response to...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199882/ https://www.ncbi.nlm.nih.gov/pubmed/34205019 http://dx.doi.org/10.3390/molecules26113382 |
_version_ | 1783707479708794880 |
---|---|
author | Akkın, Safiye Varan, Gamze Bilensoy, Erem |
author_facet | Akkın, Safiye Varan, Gamze Bilensoy, Erem |
author_sort | Akkın, Safiye |
collection | PubMed |
description | Clinically, different approaches are adopted worldwide for the treatment of cancer, which still ranks second among all causes of death. Immunotherapy for cancer treatment has been the focus of attention in recent years, aiming for an eventual antitumoral effect through the immune system response to cancer cells both prophylactically and therapeutically. The application of nanoparticulate delivery systems for cancer immunotherapy, which is defined as the use of immune system features in cancer treatment, is currently the focus of research. Nanomedicines and nanoparticulate macromolecule delivery for cancer therapy is believed to facilitate selective cytotoxicity based on passive or active targeting to tumors resulting in improved therapeutic efficacy and reduced side effects. Today, with more than 55 different nanomedicines in the market, it is possible to provide more effective cancer diagnosis and treatment by using nanotechnology. Cancer immunotherapy uses the body’s immune system to respond to cancer cells; however, this may lead to increased immune response and immunogenicity. Selectivity and targeting to cancer cells and tumors may lead the way to safer immunotherapy and nanotechnology-based delivery approaches that can help achieve the desired success in cancer treatment. |
format | Online Article Text |
id | pubmed-8199882 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81998822021-06-14 A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers Akkın, Safiye Varan, Gamze Bilensoy, Erem Molecules Review Clinically, different approaches are adopted worldwide for the treatment of cancer, which still ranks second among all causes of death. Immunotherapy for cancer treatment has been the focus of attention in recent years, aiming for an eventual antitumoral effect through the immune system response to cancer cells both prophylactically and therapeutically. The application of nanoparticulate delivery systems for cancer immunotherapy, which is defined as the use of immune system features in cancer treatment, is currently the focus of research. Nanomedicines and nanoparticulate macromolecule delivery for cancer therapy is believed to facilitate selective cytotoxicity based on passive or active targeting to tumors resulting in improved therapeutic efficacy and reduced side effects. Today, with more than 55 different nanomedicines in the market, it is possible to provide more effective cancer diagnosis and treatment by using nanotechnology. Cancer immunotherapy uses the body’s immune system to respond to cancer cells; however, this may lead to increased immune response and immunogenicity. Selectivity and targeting to cancer cells and tumors may lead the way to safer immunotherapy and nanotechnology-based delivery approaches that can help achieve the desired success in cancer treatment. MDPI 2021-06-03 /pmc/articles/PMC8199882/ /pubmed/34205019 http://dx.doi.org/10.3390/molecules26113382 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Akkın, Safiye Varan, Gamze Bilensoy, Erem A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers |
title | A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers |
title_full | A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers |
title_fullStr | A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers |
title_full_unstemmed | A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers |
title_short | A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers |
title_sort | review on cancer immunotherapy and applications of nanotechnology to chemoimmunotherapy of different cancers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199882/ https://www.ncbi.nlm.nih.gov/pubmed/34205019 http://dx.doi.org/10.3390/molecules26113382 |
work_keys_str_mv | AT akkınsafiye areviewoncancerimmunotherapyandapplicationsofnanotechnologytochemoimmunotherapyofdifferentcancers AT varangamze areviewoncancerimmunotherapyandapplicationsofnanotechnologytochemoimmunotherapyofdifferentcancers AT bilensoyerem areviewoncancerimmunotherapyandapplicationsofnanotechnologytochemoimmunotherapyofdifferentcancers AT akkınsafiye reviewoncancerimmunotherapyandapplicationsofnanotechnologytochemoimmunotherapyofdifferentcancers AT varangamze reviewoncancerimmunotherapyandapplicationsofnanotechnologytochemoimmunotherapyofdifferentcancers AT bilensoyerem reviewoncancerimmunotherapyandapplicationsofnanotechnologytochemoimmunotherapyofdifferentcancers |